BC Platforms Declares USD 20 Million Development Financing led by Jolt Capital

BC Platforms Declares USD 20 Million Development Financing led by Jolt Capital

Health Care Financing

Funding to Underpin Place as Europe’s Main Actual World Information Supplier and enabler of Personalised Precision Drugs

ZURICH, Nov. 8, 2022 /PRNewswire/ — BC Platforms (BCP), a world chief in healthcare knowledge administration and analytics, right now introduced it has closed a CHF 20 million (approx. USD 20 million) financing spherical. This development fairness financing was led by new investor Jolt Capital (HQ Paris), a completely unbiased personal fairness agency that specialises in development capital deeptech investing in Europe.

The brand new financing will assist speed up the growth of the corporate’s knowledge footprint, consolidating the corporate’s place because the main European knowledge supplier, and enabler of personalised precision drugs, with a concentrate on sourcing clinically beneficial Actual-World Information (RWD) from European and Asian nations. The aim is to supply customers of BCP’s providers, which embody over ten of the world’s largest pharmaceutical corporations, with over 100 million accessible topics by 2026.

The financing can even speed up the know-how management of the corporate’s platform regarding knowledge privateness, knowledge harmonising functionalities and federated machine studying (AI) which might quickly ship highly effective insights to life science researchers and clinicians. BCP’s providers enhance the velocity of drug growth, particularly round offering high-value healthcare knowledge that accelerates trade’s analysis innovation, offering impactful R&D insights to deliver simpler medication to market extra rapidly, enabling inexpensive therapy developments for uncommon ailments. A significant a part of this core experience consists of BCP’s ‘Trusted Collaboration Surroundings’ (TCE).  The financing can even be used to put money into BCP’s R&D protection and develop its gross sales and advertising and marketing operations throughout the globe. The corporate is already current within the US, the UK, Finland, Switzerland, and Singapore.

Tero Silvola, CEO of BCP, mentioned, “Jolt Capital is the reference investor for European deeptech fairness, and we’re delighted that they’ve recognised us as a frontrunner in our house. This important funding offers a robust enhance on our mission to turning into Europe’s main knowledge supplier, focussed on top quality RWD from a number of nations throughout a number of continents. Extra various affected person knowledge means higher outcomes for sufferers, researchers, and society as a complete, as diagnostic and medicines are developed with the widest and quickest doable applicability. We can even be trying to construct synergistic capabilities by future acquisitions.”

Laurent Samama, Managing Accomplice at Jolt Capital, mentioned, “As we’re used to scale accountable deeptech corporations from Europe, we noticed the outstanding energy in BCP’s genomic knowledge discovery and analytics platforms. Entry to various and distinctive affected person knowledge, and samples, is turning into basic to the success of biotech and pharma corporations, and the world’s future well being. This can be a appreciable and fast-growing market the place BCP is on observe to emerge as a world chief.”

TCE is a collaboration optimised setting created to make sure that healthcare organisations can share knowledge with researchers globally whereas adhering to their native regulatory and privateness necessities. BCP has designed TCE to degree the regulatory enjoying area for entry to real-world knowledge. It protects proprietary algorithms used to assist synthetic intelligence and machine studying approaches for higher sample recognition. TCE ensures that the builders of recent medicines can concentrate on their analysis. As BCP originates from inside Europe, it basically understands European knowledge privateness, and its distinctive knowledge assortment know-how offers important compliance benefits for drug builders. For extra about BCP’s TCE providers, verify right here:


About BC Platforms

BC Platforms is a world chief in constructing knowledge networks for the life sciences trade and offers versatile know-how platforms for personalised drugs, accelerating the interpretation of improvements into medical observe. We convert advanced organic data collected within the healthcare setting into actionable insights. With our modern know-how we’re making a affected person centric infinity loop between the life sciences and healthcare sectors. Information we generate, harmonise, and handle, from various biobanks and healthcare establishments, is made accessible for pharmaceutical and biotech corporations to boost their core strengths in analysis and growth. In parallel, we allow stratification of sufferers in the direction of focused therapies, delivering on the promise of extra personalised healthcare.

Our excessive performing genomic knowledge discovery and analytics platform permits versatile knowledge integration, safe evaluation, and interpretation of molecular and medical data. We’ve got developed a World Information Accomplice Community, BCRQUEST.com, which permits entry to high-quality real-world knowledge. This quickly rising community has a footprint throughout many websites, together with networks of main hospitals, protecting 20 nations on 5 continents, offering commonplace of care knowledge for over 23 million sufferers. Our platforms seamlessly facilitate entry to extremely enriched knowledge for pharmaceutical analysis and growth.

Based in 1997 from a MIT Whitehead venture spinoff, we’ve a powerful scientific heritage underpinned by over 25 years of working in shut collaboration with a community of main researchers, builders, and trade companions. We’ve got international operations with our headquarters in Zurich, Switzerland, R&D in Espoo, Finland, and Singapore, in addition to a presence in London and Boston. For extra data, go to our web site and observe us on LinkedIn.    

About Jolt Capital (www.jolt-capital.com)

Jolt Capital is an unbiased personal fairness agency specialised in development investing in superior know-how corporations, with a mission to construct future European leaders with a world focus. Since 2011, Jolt Capital invests in European B2B corporations with revenues between €10M and €50M. Jolt Capital’s staff consists solely of skilled traders and managers of high-tech corporations. Its proprietary AI platform, Jolt.Ninja, permits enriched sourcing, accelerated due diligence and computerized detection of funding or acquisition targets. Jolt Capital is in Paris, Lausanne, Copenhagen, and Milan.

CONTACT: [email protected]

Brand – https://mma.prnewswire.com/media/1940673/Jolt_Capital_Logo.jpg

SOURCE Jolt Capital

BC Platforms Declares USD 20 Million Development Financing led by Jolt Capital